| # | Drug | Count |
|---|---|---|
| 0 | BEVACIZUMAB | 6 |
| 1 | PACLITAXEL | 6 |
| 2 | PEMBROLIZUMAB | 4 |
| 3 | RAMUCIRUMAB | 4 |
| 4 | REGORAFENIB | 4 |
| 5 | ATEZOLIZUMAB | 3 |
| 6 | CARBOPLATIN | 3 |
| 7 | NIVOLUMAB | 3 |
| 8 | DOCETAXEL | 2 |
| 9 | DOCETAXEL ANHYDROUS | 2 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | NALDEMEDINE | 1 | 0.0011 |
| 1 | RAMUCIRUMAB | 4 | 0.0010 |
| 2 | REGORAFENIB | 4 | 0.0005 |
| 3 | ATEZOLIZUMAB | 3 | 0.0002 |
| 4 | AFATINIB | 1 | 0.0002 |
| 5 | LENVATINIB | 2 | 0.0002 |
| 6 | PEMBROLIZUMAB | 4 | 0.0001 |
| 7 | PACLITAXEL | 6 | 0.0001 |
| 8 | SUVOREXANT | 1 | 0.0001 |
| 9 | BEVACIZUMAB | 6 | 0.0001 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 4 | 0.0010 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 10 | 0.0001 |
| 2 | Orexin Receptor Antagonist [EPC] | 1 | 0.0001 |
| 3 | Microtubule Inhibitor [EPC] | 8 | 0.0001 |
| 4 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 6 | 0.0000 |
| 5 | Platinum-based Drug [EPC] | 4 | 0.0000 |
| 6 | Leukocyte Growth Factor [EPC] | 1 | 0.0000 |
| 7 | Kinase Inhibitor [EPC] | 3 | 0.0000 |
| 8 | Nucleoside Metabolic Inhibitor [EPC] | 1 | 0.0000 |
| 9 | Benzodiazepine [EPC] | 1 | 0.0000 |